A 47-year-old woman had a history of episodic acute intermittent angioedema and urticaria with moderate pruritus for one month. She was on 10 mg of loratadine daily. She had a fever of 39°C, arthralgia, fatigue, and angioedema of the upper respiratory tract. Laboratory results are shown in [Table 1](#T0001){ref-type="table"}. She had elevated IgE (206 kU/L). The immunoassay for C1-esterase inhibitor was normal. She was treated with H1- and H2-blocking antihistamines, and methylprednisolone intravenously (1 mg/kg/day). Culture results and viral titers were negative except for a high positive titer of specific IgG antibody to parvovirus B19 of 11.1 (positive titer \>1). On the third week of hospitalization, she deteriorated rapidly and developed a macular rash on the trunk and extremities with generalised lymphadenpathy, liver dysfunction and disseminated intravascular coagulopathy (DIC) ([Figure 1](#F0001){ref-type="fig"}). A skin biopsy specimen was compatible with lymphocytic lichenoid vasculitis. An inflammatory pattern centered on the basal layer of the epidermis and upper dermis in a dense band-like distribution. Direct immunofluorescence showed no IgG, IgA, IgM, C3, C1q and fibrinogen deposits. A bone marrow aspirate showed hemophagocytosis ([Figure 2](#F0002){ref-type="fig"}). Parvovirus B19 DNA was detected by the polymerase chain reaction (PCR) in bone marrow ([Figure 3](#F0003){ref-type="fig"}). Macrophage activation syndrome was confirmed. The patient was treated with methylprednisolone 250 mg/day intravenously and intravenous immunoglobulin (IVIG) 0.55 g/kg BW/day for five consecutive days, followed by methylprednisolone 1 mg/kg daily. Fresh frozen plasma and enoxaparin were administered. Two days after treatment, she improved. Monthly infusions of IVIG were continued for 6 months. Corticosteroids were tapered gradually to 8 mg of methylprednisolone daily. On periodic follow-up, the patient was quite well without episodes of angioedema and no new skin lesions were seen. Our patient met all criteria for reactive macrophage activation syndrome (rMAS) outlined by Imashuku.[@CIT1]

###### 

Laboratory test results.

  Laboratory data (normal values in parenthesis)   Admission   Before IVIG[a](#T000F1){ref-type="table-fn"}   After first IVIG[a](#T000F1){ref-type="table-fn"}
  ------------------------------------------------ ----------- ---------------------------------------------- ---------------------------------------------------
  Erythrocyte sedimentation rate (2-13 mm/h)       57          16                                             122
  White blood cell count (4-10×10^9^/L)            11.8        5.8                                            11.0
  Hemoglobin (120-160 g/L)                         132         78                                             101
  Platelet count (140-440×10^9^/L)                 203         33                                             249
  C reactive protein (0-5 mg/L)                    143         88.2                                           28.7
  Aspartate aminotransferase (7-49 IU/L)           28          720                                            54
  Alanine aminotransferase (7-49 IU/L)             35          500                                            75
  Lactate dehydrogenase (170-430 IU/L)             361         3206                                           335
  Ferritin (10-300 mg/L)                           12200       43700                                          8300
  Fibrinogen (2-4.5 g/L)                           6.1         1.4                                            4.0
  D-dimer (0.06-0.25 mg/ml)                        0.15        4.36                                           0.30

IVIG = intravenous immunoglobulin

![Maculopapular rash.](ASM-30-88-g001){#F0001}

![Bone marrow aspirate shows increased number of histiocytes with active hemophagocytosis (Hematoxylin stain ×200 magnification).](ASM-30-88-g002){#F0002}

![Real-time PCR that confirmed parvovirus B19 (arrow shows negative control sample).](ASM-30-88-g003){#F0003}

Acute parvovirus B19 infection can be diagnosed by demonstrating a four-fold rise in serum B19-specific IgG antibody titers, as in our case. B19 specific DNA or antigens can be detected for months or even years after infection.[@CIT2][@CIT3] We speculate that the presence of acute parvovirus B19 infection was a trigger for rMAS.[@CIT4] Lymphocytic vasculitis is a reactive process.[@CIT5][@CIT6] Purpura pigmentosa chronica, fixed drug eruption, urticarial vasculitis, allergic vasculitis, and the vasculitis of Sjogren syndrome are known to have lymphocytic vasculitis. We conclude that rMAS might represent a subgroup of patients with systemic inflammatory response amenable to IVIG treatment. Given early, IVIG may interrupt the processes that lead to macrophage overactivation.
